- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Isosorbide ( Isosorbide )
Isosorbide mononitrate is a long-acting organic nitrate vasodilator indicated for the prophylactic management of chronic stable angina pectoris. It is the active 5-mononitrate metabolite of isosorbide dinitrate and works by undergoing intracellular biotransformation to nitric oxide, a potent activator of the enzyme guanylate cyclase in vascular smooth muscle cells. The resulting increase in cyclic guanosine monophosphate (cGMP) leads to dephosphorylation of myosin light chains and relaxation of vascular smooth muscle, producing dilation of both peripheral veins and arteries. Venodilation predominates, reducing venous return and ventricular preload, thereby decreasing myocardial wall tension and oxygen demand. Arterial dilation reduces systemic vascular resistance and afterload, further lowering cardiac work. In addition, isosorbide mononitrate dilates epicardial coronary arteries and improves collateral blood flow to ischemic myocardial regions. It is not intended for the acute termination of an anginal attack; sublingual nitroglycerin should be used for immediate relief of acute symptoms.
Usual adult dose: The recommended starting dose is 20 mg to 30 mg administered twice daily, with the two doses given 7 hours apart to maintain a nitrate-free interval. A typical dosing schedule is to take the first dose upon awakening and the second dose 7 hours later, ensuring a 17-hour nitrate-free period overnight. This nitrate-free interval is critical to minimize the development of nitrate tolerance, which can render the medication ineffective. For patients requiring higher doses, 40 mg or 60 mg may be administered twice daily following the same asymmetric dosing schedule. Alternatively, extended-release formulations (Imdur) are available as 30 mg, 60 mg, or 120 mg tablets administered once daily upon awakening. The dose should be titrated to the lowest effective level that achieves satisfactory angina prophylaxis while minimizing adverse effects such as headache. Abrupt discontinuation should be avoided; the dose should be tapered over several weeks to prevent rebound angina in patients on chronic therapy.
Dosage form: Tablets: 20 mg (white, round, scored), 30 mg (white, round, scored), 40 mg (white, round, scored), and 60 mg (white, round, scored). Extended-release tablets (Imdur) are available as 30 mg, 60 mg, and 120 mg oval, film-coated tablets for once-daily administration. The scored design of the immediate-release tablets allows for dose adjustments and flexible titration.
Onset of action: Following oral administration, isosorbide mononitrate is rapidly and completely absorbed from the gastrointestinal tract, with peak plasma concentrations achieved within approximately 30 to 60 minutes for immediate-release tablets. The anti-anginal prophylactic effect begins within approximately 30 minutes of dosing. Extended-release formulations produce a slower onset with peak concentrations at 3 to 4 hours, providing a gradual rise in plasma levels that may improve tolerability. Steady-state plasma concentrations are achieved within 2 to 3 days of regular twice-daily dosing.
Duration of action: The elimination half-life of isosorbide mononitrate is approximately 4 to 5 hours. The anti-anginal effect of immediate-release formulations persists for approximately 5 to 7 hours, consistent with the recommended twice-daily asymmetric dosing schedule. Extended-release formulations provide approximately 12 hours of anti-anginal coverage, followed by a nitrate-free interval during the latter portion of the dosing interval. The active metabolite isosorbide is pharmacologically inert, and the drug undergoes predominantly renal elimination.
Alcohol recommendation: Alcohol consumption should be minimized or avoided during treatment with isosorbide mononitrate. Both alcohol and organic nitrates produce vasodilation, and their combined use can result in additive hypotensive effects, including significant reductions in blood pressure, dizziness, lightheadedness, orthostatic hypotension, and syncope. Patients should be cautioned about the potential for severe postural hypotension, particularly when rising from a sitting or lying position. If alcohol is consumed, intake should be limited and patients should understand how the combination affects them before driving or operating machinery.
Most common side effects: Headache is the most frequently reported adverse effect, occurring in up to 50% to 80% of patients during the initial weeks of therapy. Nitrate-induced headaches are typically throbbing, bifrontal, and dose-related, reflecting cerebral vasodilation. These headaches generally diminish in intensity with continued treatment over 1 to 2 weeks. Other common side effects include dizziness, lightheadedness, flushing of the face and neck, orthostatic hypotension, and reflex tachycardia. Less frequently, patients may experience nausea, vomiting, or a sensation of warmth. Nitrate tolerance, characterized by the progressive diminution of therapeutic efficacy with sustained exposure, is a clinically significant concern; strict adherence to the nitrate-free interval is essential to maintain anti-anginal efficacy. Methemoglobinemia is a rare but serious adverse effect associated with nitrate therapy. Isosorbide mononitrate is absolutely contraindicated in patients taking phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil, tadalafil, or vardenafil, as the combination can precipitate profound, life-threatening hypotension.
Would you like to learn more about isosorbide mononitrate for the prevention of chronic stable angina?
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
